1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Correlates of work status during adjuvant chemo- or radiation therapy for breast cancer
    Meeting Abstract

    Blinder, V. S.; Eberle, C. E.; Patil, S.; Oeffinger, K. C.; Bradley, C.; Gany, F.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses
    Meeting Abstract

    Borghaei, H.; Brahmer, J. R.; Horn, L.; Ready, N.; Steins, M.; Felip, E.; Paz-Ares, L. G.; Arrieta, O.; Barlesi, F.; Antonia, S. J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel plus cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer
    Meeting Abstract

    Blum, J. L.; Flynn, P. J.; Yothers, G.; Asrnar, L.; Geyer, C. E.; Jacobs, S. A.; Robert, N. J.; Atkins, J. N.; O'Shaughnessy, J.; Dang, C. T.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Changes in body composition and prognostic importance of sarcopenia in patients receiving CTRT for oropharyngeal cancer
    Meeting Abstract

    Baxi, S. S.; Jones, L.; Eaton, A.; Gandelman, S.; Halpenny, D.; Jackson, J.; Kurtzman, R.; McBride, S. M.; Plodkowski, A.; Pfister, D. G.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Bauml, J.; Seiwert, T. Y.; Pfister, D. G.; Worden, F. P.; Liu, S. V.; Gilbert, J.; Saba, N. F.; Weiss, J.; Wirth, L. J.; Sukari, A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)
    Meeting Abstract

    Bendell, J. C.; Kim, T. W.; Goh, B. C.; Wallin, J.; Oh, D. Y.; Han, S. W.; Lee, C. B.; Hellmann, M. D.; Desai, J.; Lewin, J. H.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Identification of genetic test results with conflicting interpretations in prospective registry of multiplex testing (PROMPT)
    Meeting Abstract

    Balmana, J.; Digiovanni, L.; Gaddam, P.; Walsh, M. F.; Garber, J. E.; Couch, F. J.; Offit, K.; Robson, M. E.; Domchek, S. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts)
    Meeting Abstract

    Bajorin, D. F.; Sharma, P.; Quinn, D. I.; Plimack, E. R.; Hoffman-Censits, J. H.; O'Donnell, P. H.; Siefker-Radtke, A. O.; Sheikh, N. A.; Lill, J. S.; Trager, J. B.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Prevalence, risk factors, and sequelae of long-term chemotherapy-induced peripheral neuropathy (CIPN) among breast cancer survivors
    Meeting Abstract

    Bao, T.; Li, S. Q.; Mao, J. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR plus triple negative (TNBC) or estrogen receptor (ER) plus breast cancer (BC)
    Meeting Abstract

    Bardia, A.; Dacosta, N. A.; Gabrail, N. Y.; Lemon, S.; Danso, M. A.; Ali, H. Y.; Fleming, R. A.; Kurman, M. R.; Eisner, J. R.; Moore, W. R.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save